Continued access to encorafenib and binimetinib for prior trial participants
Treatments studied
Part of Cancer clinical trials.
This study lets people who were already getting encorafenib and binimetinib in an earlier trial keep taking these medicines if they are doing well on them. It provides a way to continue treatment without a gap.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are currently receiving encorafenib and binimetinib in another clinical trial.
- Your doctor believes you are getting real benefit from these medicines.
- You do not have any severe or intolerable side effects from the treatment.
- You agree to follow the study's rules about contraception and pregnancy prevention.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial allows people with solid tumors who are already benefiting from the study drug adagrasib in an earlier Mirati study to continue getting it for the long term. It’s for people whose doctors see ongoing benefit and who still meet the safety rules.
This study lets people who finished a prior dabrafenib/trametinib trial (sponsored by Novartis or former GSK) continue those medicines if the study doctor thinks it will help. It mainly focuses on ongoing treatment benefit rather than testing a new drug.
This trial tests adding a new chemotherapy regimen (FOLFIRI) to the combination of Encorafenib and Cetuximab for people with a specific type of advanced colorectal cancer that has started growing again after initial treatment with Encorafenib and Cetuximab. The goal is to see if the new combination can help control the cancer longer.
This trial studies how doctors use encorafenib plus binimetinib for real-world care in people with BRAF V600–mutated melanoma that can’t be removed by surgery or has spread. It may help improve understanding of which patients benefit and what happens in everyday clinical practice.
This trial tests whether giving the drugs encorafenib and cetuximab again (rechallenge) can help people with BRAF V600E-mutant metastatic colorectal cancer whose disease has progressed after previous BRAF inhibitor-based therapy. It aims to see if this combination can be beneficial after a break from that type of treatment.
This trial tests whether giving encorafenib and cetuximab before surgery can shrink or control BRAF-mutated colon or upper rectal cancer and make surgery more effective. It also checks whether this approach is safe and helps patients do better overall.
Hear when a new Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.